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with pharmacist-managed ESA clinics (n314) and at six sites with usual care only
(n167); outpatients were followed for 6months in 2009.We took a VA perspective
with projections over a five-year time horizon; costs and effectiveness values were
discounted at 3%/yr. Strategy-specific likelihoods of target range hemoglobin val-
ues (10-12 g/dl) were based on study results. Utilities for ND-CKD and ESA-related
adverse events and their likelihood were obtained from the literature. ESA costs
were based on average monthly epoetin and darbepoetin doses per patient during
the study and VA ESA cost data. RESULTS: In the base case analysis, cost and effec-
tivenesswere$12,500and2.096quality-adjusted life-years (QALYs) in thepharmacist-
managed ESA clinics and $15,500 and 2.093 QALYs in usual care; ESA clinics domi-
nated usual care. In one-way sensitivity analyses, ESA clinics no longer dominated if
theirpatients’probabilityofbeing in the target range fell to0.54 (basecase0.71)or if the
mean cost/month of epoetin or darbepoetin in ESA clinics increased to approximately
$360 (base case $211) or $460 (base case $250), respectively.When all parameterswere
varied simultaneously in a probabilistic sensitivity analysis, ESA clinics were favored
80% of the time regardless of willingness-to-pay threshold. CONCLUSIONS: Phar-
macist-managed ESA clinics were less costly and more effective than usual care in
patients receiving ESAs for anemia andND-CKD. Results were robust to variation and
support the use of pharmacist-managed ESA clinics.
PUK20
COST-UTILITY ASSESSMENT OF SIROLIMUS VERSUS TACROLIMUS FOR
PRIMARY PREVENTION OF GRAFT REJECTION IN RENAL TRANSPLANT
RECIPIENTS IN MEXICO
Rely K1, Alexandre PK2, García-García EG3, Muciño-Ortega E3, Salinas-escudero G4,
Galindo-Suárez RM3
1CEAHealthTech, Mexico City, D.F., Mexico, 2Johns Hopkins University, Baltimore, MD, USA,
3Pfizer S.A. de C.V., Mexico City, Mexico, 4Hospital Infantil de México Federico Gómez, Secretaría
de Salud, Mexico City, Distrito Federal, Mexico
OBJECTIVES: Immunosuppressive agents have affected the incidence of acute re-
jection and early graft survival. The purpose of this study was to evaluate the
cost-utility of sirolimus versus tacrolimus for primary prevention of graft rejection
in renal transplant recipients using the Mexican Institute of Social Security (IMSS)
perspective. METHODS: A Markov model was developed to estimate the cost-ef-
fectiveness of sirolimus versus tacrolimus to prevent graft rejection in adult pa-
tients with end-stage renal disease (ESRD). The model estimates total costs and
QALYs per patient in each prophylaxis group. To extrapolate trial results to lifetime
horizon, the model was extended through one-year Markov cycles. The probabili-
ties of experiencing a graft loss, dialysis, and death were estimated from trial
published data; long-term mortality, acquisition costs, and direct treatment costs
were retrieved using IMSS published sources. Cost utility assessment was ex-
pressed in terms of cost per QALY gained. All costs are presented in 2011US dollars.
Probabilistic sensitivity analyses were carried out to test the robustness of the
results. RESULTS: In comparison to tracolimus, sirolimus improved life expec-
tancy, number of QALYs gained, and reduced incidence of complications. The life-
time overall costs of prevent graft rejection in adult patients with ESRD resulted in
a cost per QALY gained of $5846. Over the lifetime period, sirolimus was esti-
mated to gain 8.18 QALYs per patient compared to 7.33 QALYs for tacrolimus.
Sirolimus is estimated to be cost-saving compared to tacrolimus. Notably, results
suggest that sirolimus has a 78% probability of being dominant over tacrolimus
strategy, with 100% of probability in showing an incremental cost-effectiveness
ratio at or below US$13,000 (1 GDP per capita in Mexico) per QALY gained.
CONCLUSIONS: This analysis suggests that at IMSS, sirolimus in comparison to
tacrolimus for prevention of graft rejection in adults patient with ESRD is likely to
be cost saving alternative.
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OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment of
patients with overactive bladder (OAB) with solifenacin 5 mg/day versus either
trospium 20mg twice a day or trospium 60 mg/day from the perspective of the
German National Health Service. METHODS: A decision analytic model with a
three-month cycle was developed to follow a cohort of OAB patients treated with
either solifenacin or trospium during a one-year period. Costs and utilities were
accumulated as patients transitioned through the four cycles in themodel. Some of
the solifenacin patients were titrated from 5mg to 10mg/day at 3 months. Utility
values were obtained from the published literature and pad use was based on a US
resource utilisation study. Adherence rates for individual treatments were derived
from a UK GP database review. The change in themean number of urgency urinary
incontinence episodes/day from after 12 weeks was the main outcome measure.
Baseline effectiveness values for solifenacin and trospium were calculated using
the Poisson distribution. Patients who failed second-line therapy were referred for
a specialist visit. Results were expressed in terms of incremental cost-utility ratios.
RESULTS: Total annual costs for solifenacin, trospium 20mg and trospium 60mg
were 982.28 €, 863.23 € and 880.37 € respectively. Drug use represented 47%, 32%and
33% of total costs and pad use varied between 42% and 55%. Differences between
cumulative utilities were small but favoured solifenacin (0.6887 vs. 0.6828 to
0.6830). The baseline incremental cost-effectiveness ratio ranged from 17,104 € to
20,533 per QALY. CONCLUSIONS: Solifenacin would appear to be cost-effective
with an incremental cost-utility of no more than 21,000 €/QALY. Small differences
in utility between the alternatives, however,means that the results are sensitive to
adjustments in the values of the assigned utilities, effectiveness and discontinua-
tion rates.
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OBJECTIVES: To compare the utility scores and quality of life scores between pa-
tients who have twice and thrice-weekly hemodialysis. METHODS: This was a
cross-sectional analytical study in 5 hemodialysis sites ofNephrologyUnit at Siriraj
Hospital (the largest university hospital in Thailand), Face-to-face interview using
EuroQol questionnaire (EQ-5D), VAS, and KDQOL-36 (consists of 3 kidney disease
subscales and SF-12) was conducted between April 2011 and June 2011, one hun-
dred and fifty-three hemodialysis patients were recruited from the chronic hemo-
dialysis clinic unit. This study compared the difference of hemodialysis times in
weekly to utility scores and quality of life scores of patients by using Independent
Student’s t-test. RESULTS: SF-6D (derived from SF12), EQ-5D (UK and Thai prefer-
ence weight), and VAS between the patients who received twice and thrice-weekly
hemodialysis were not significantly different (p0.05). This is true as well for
Symptom/ problem list, Effects of kidney disease, and burden of Kidney Disease
scores. For SF-12, all of physical and mental domains were not significantly differ-
ent as well as all of utility and kidney disease specific scores were not significantly
associated with hemodialysis times in weekly intervals (all, p0.05).
CONCLUSIONS: These findings implied that thrice-weekly could not reflect the
better quality of life than twice-weekly hemodialysis. There was no significant
difference quality of life from the Symptom/ problem list, Effects of kidney disease,
and burden of Kidney Disease between twice and thrice-weekly hemodialysis as
well as the utility scores from SF-6D, EQ-5D and VAS. Further large cohort study of
utility scores or cost effectiveness analysis between the difference of dialysis fre-
quency at weekly intervals, however, should be conducted.
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OBJECTIVES: Analysis of EQ-5D data often focuses on changes in utility, ignoring
valuable information from other parts of the instrument. Our objective was to
explore how the utility index, EQ-5D profile, and EQ-VAS captured change in clin-
ical trials of Mirabegron, a new treatment for overactive bladder (OAB).METHODS:
Data were pooled from three phase III clinical trials that investigated the efficacy
and safety of mirabegron versus placebo. Tolterodine ER 4mg was included as an
active control in one study: 1) Europe and Australia (placebo,mirabegron 50mg and
100mg, and tolterodine 4mg ER); 2) USA andCanada (Placebo,Mirabegron 50mg and
100mg); and 3) USA, Canada and Europe (Placebo, and Mirabegron 25mg and 50mg.
Data were collected at baseline, week 4, 8 and 12. Analyses were performed on full
analysis and per protocol data sets using UK utilities. Analysis controlled for rele-
vant patient characteristics. Analysis of Covariance identified changes from base-
line at each time point in utilities and EQ-VAS, while Areas Under the Curve (AUC)
were estimated to summarise intertemporal differences in effect. RESULTS: In per
protocol analyses, mirabegron 50mg was superior to tolterodine 4mg in changes
from baseline utilities after 12 weeks (p0.05); similarly, AUC results showed mi-
rabegron 50mg to be superior to tolterodine (p0.05) and to placebo (p0.05). In
both cases, the benefit is already apparent at 4 weeks (p0.05). EQ-VAS more con-
sistently indicated superior outcomes: all three mirabegron doses showed statisti-
cally significant greater effectiveness compared to tolterodine at 12 weeks. Indi-
vidual EQ-5D dimensions and the overall profile showed no significant differences
between study arms. CONCLUSIONS: Despite slight contrasts in results between
the EQ-5D derived utilities and EQ-VAS, mirabegron showed quicker and superior
improvement in HR-QoL compared to tolterodine 4mg ER. Research is required to
address future utilitymeasurements, especially in relation to EQ-5D dimensions in
OAB patients.
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OBJECTIVES: Examine role of caregiver in supporting treatment decisions towards
blood transfusions among individuals with chronic kidney disease (CKD) currently
not on dialysis.METHODS: An online survey was conducted in 1Q2011. All respon-
dents were18 years and diagnosed with Cancer by a physician. Participants were
asked about blood transfusion history, presence of anemia, types and roles of
caregivers in assisting with management of their CKD and making health and
treatment decisions towards blood transfusion. RESULTS: Of 416 participants, 59%
(n246)were female; 40% (n165)were65 years. 35% (n144) had stage 4 and 58%
(n240) stage 3 CKD. 54% (n226) were anemic. 43% (n179) had received blood
transfusion, whereas, 57% (n237) had no transfusions. 53% (n220) reported that
A156 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
